Powered by

Amgen adds cholesterol fighter Dezima Pharma for upward of $1.55B

Sep 17, 2015 - The Deal Pipeline
Mergers and Acquisitions

Amgen Inc. said Wednesday it would acquire privately held Dezima Pharma BV for an initial $300 million, increasing the pharmaceutical company's portfolio of cholesterol-management drugs. Dezima was founded in 2012 by researchers at the Academic Medical Center of the University of Amsterdam with funding by Forbion Capital Partners.

The Naarden, Netherlands-based company's lead molecule, TA-8995, is a once-daily treatment for patients with elevated levels of bad cholesterol. It has co...